NASDAQ:XENE

Xenon Pharmaceuticals - XENE Stock Forecast, Price & News

$38.30

+1.17 (+3.15%)

(As of 10/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $36.65
▼
$38.38
50-Day Range: $31.68
▼
$39.82
52-Week Range: $23.26
▼
$41.39

Volume: 191,085 shs
Average Volume: 398,392 shs
Market Capitalization: $2.38 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $47.80

Xenon Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 24.8% Upside
$47.80 Price Target
Short Interest: Bearish
4.16% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.42
Based on 5 Articles This Week
Insider Trading: Selling Shares
$6.98 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.05) to ($2.86) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

714th out of 1,075 stocks

Pharmaceutical Preparations Industry

335th out of 537 stocks

2.5

Analyst's Opinion

Consensus Rating
Xenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.80, Xenon Pharmaceuticals has a forecasted upside of 24.8% from its current price of $38.30.
Amount of Analyst Coverage
Xenon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.16% of the outstanding shares of Xenon Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.
Change versus previous month
Short interest in Xenon Pharmaceuticals has recently increased by 9.75%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Xenon Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Xenon Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for XENE.

1.9

News and Social Media Coverage

News Sentiment
Xenon Pharmaceuticals has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Xenon Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,982,432.00 in company stock.
Percentage Held by Insiders
Only 6.06% of the stock of Xenon Pharmaceuticals is held by insiders.
Percentage Held by Institutions
91.64% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($2.05) to ($2.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Xenon Pharmaceuticals is -20.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Xenon Pharmaceuticals is -20.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Xenon Pharmaceuticals has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Stock News Headlines

October 7, 2022 | americanbankingnews.com

Traders Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

October 6, 2022 | finance.yahoo.com

Are Investors Undervaluing Xenon Pharmaceuticals Inc. (NASDAQ:XENE) By 32%?

October 6, 2022 | finance.yahoo.com

Xenon Pharmaceuticals Inc. (XENE)

September 21, 2022 | seekingalpha.com

XENE Xenon Pharmaceuticals Inc.

September 1, 2022 | finance.yahoo.com

Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

August 29, 2022 | finance.yahoo.com

10 Best Biotech Stocks To Buy Now

August 29, 2022 | markets.businessinsider.com

Analyst Ratings for Xenon Pharmaceuticals

August 18, 2022 | seekingalpha.com

Xenon Pharmaceuticals (XENE) Investor Presentation - Slideshow

August 12, 2022 | finance.yahoo.com

What Does The Future Hold For Xenon Pharmaceuticals Inc. (NASDAQ:XENE)? These Analysts Have Been Cutting Their Estimates

August 11, 2022 | markets.businessinsider.com

4 Analysts Have This to Say About Xenon Pharmaceuticals

August 10, 2022 | seekingalpha.com

Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q2 2022 Results - Earnings Call Transcript

August 10, 2022 | nasdaq.com

An Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 23% Undervalued

August 9, 2022 | finance.yahoo.com

Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates

August 9, 2022 | finance.yahoo.com

Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 8, 2022 | finance.yahoo.com

Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference

August 2, 2022 | finance.yahoo.com

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update

July 22, 2022 | finance.yahoo.com

What Type Of Shareholders Own The Most Number of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares?

July 21, 2022 | seekingalpha.com

Xenon added to JP Morgan’s analyst focus list citing lead asset

June 27, 2022 | finance.yahoo.com

Xenon Pharmaceuticals' (NASDAQ:XENE) investors will be pleased with their enviable 884% return over the last five years

June 27, 2022 | finance.yahoo.com

Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

June 23, 2022 | finance.yahoo.com

Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency

June 23, 2022 | finance.yahoo.com

Why Xenon Pharma Flirted With A Breakout — And Then Sacrificed It All

June 23, 2022 | seekingalpha.com

Hot Stocks: OXY rises as Buffett adds shares, SNOW pops on upgrade, KBH also gains and XENE declines

June 23, 2022 | seekingalpha.com

Xenon Pharmaceuticals slides on pricing $250M equity offering

June 22, 2022 | finance.yahoo.com

Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Company Calendar

Last Earnings: 8/09/2022
Today: 10/07/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XENE
CUSIP: N/A
CIK: 1582313
Web: www.xenon-pharma.com
Phone: (604) 484-3300
Fax: 604-484-3450
Employees: 149
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $47.80
High Stock Price Forecast: $55.00
Low Stock Price Forecast: $43.00
Forecasted Upside/Downside: +24.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-78,880,000.00
Net Margins: -432.24%
Pretax Margin: -434.68%
Return on Equity: -17.33%
Return on Assets: -16.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 57.86
Quick Ratio: 57.86

Sales & Book Value

Annual Sales: $18.44 million
Price / Sales: 129.31
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.51 per share
Price / Book: 3.64

Miscellaneous

Outstanding Shares: 62,260,000
Free Float: 58,490,000
Market Cap: $2.38 billion
Optionable: Optionable
Beta: 1.46

Key Executives

Mr. Ian C. Mortimer C.M.A. (Age 46)
CPA, CMA, CPA, M.B.A., MBA, Pres, CEO & Director
Comp: $957.16k

Ms. Sherry Aulin (Age 38)
Chief Financial Officer
Comp: $458.64k

Dr. Christopher John Kenney M.D. (Age 51)
Chief Medical Officer
Comp: $494.83k

Ms. Jodi Regts M.B.A.
B.A., MBA, VP of Corp. Affairs & Investor Relations

Ms. Shelley McCloskey B.A. (Age 62)
Exec. VP of HR

Dr. Robin P. Sherrington Ph.D. (Age 61)
Exec. VP of Strategy & Innovation

Dr. James R. Empfield Ph.D. (Age 61)
Exec. VP of Drug Discovery

Ms. Sheila M. Grant M.B.A.
M.Sc., MBA, Exec. VP of R&D Operations

Dr. Christopher E. Von Seggern M.B.A. (Age 43)
M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer

Dr. Kenneth Sommerville
Interim Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XENE Stock - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares.
View XENE analyst ratings or view top-rated stocks.
What is Xenon Pharmaceuticals' stock price forecast for 2022?: 6 Wall Street analysts have issued 1-year target prices for Xenon Pharmaceuticals' stock. Their XENE share price forecasts range from $43.00 to $55.00. On average, they anticipate the company's stock price to reach $47.80 in the next twelve months. This suggests a possible upside of 24.8% from the stock's current price.
View analysts price targets for XENE or view top-rated stocks among Wall Street analysts.
How have XENE shares performed in 2022?: Xenon Pharmaceuticals' stock was trading at $31.24 at the start of the year. Since then, XENE stock has increased by 22.6% and is now trading at $38.30.
View the best growth stocks for 2022 here.
When is Xenon Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our XENE earnings forecast.
How were Xenon Pharmaceuticals' earnings last quarter?: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.06. The biopharmaceutical company had revenue of $0.54 million for the quarter, compared to analyst estimates of $3.25 million. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 17.33% and a negative net margin of 432.24%. The business's revenue for the quarter was down 75.8% on a year-over-year basis. During the same period last year, the firm posted ($0.51) earnings per share.

What other stocks do shareholders of Xenon Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).
What is Xenon Pharmaceuticals' stock symbol?: Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How do I buy shares of Xenon Pharmaceuticals?: Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Xenon Pharmaceuticals' stock price today?: One share of XENE stock can currently be purchased for approximately $38.30.
How much money does Xenon Pharmaceuticals make?: Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.38 billion and generates $18.44 million in revenue each year. The biopharmaceutical company earns $-78,880,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.
How many employees does Xenon Pharmaceuticals have?: The company employs 149 workers across the globe.
How can I contact Xenon Pharmaceuticals?: Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.

This page (NASDAQ:XENE) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Xenon Pharmaceuticals - XENE Stock Forecast, Price & News

Xenon Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month